Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 13Prostatic Neoplasms 11Leukemia 11Breast Neoplasms 11Melanoma 8Lymphoma 8Lymphoma, Non-Hodgkin 7Leukemia, Lymphocytic, Chronic, B-Cell 7Neoplasm Metastasis 6Myelodysplastic Syndromes 6Multiple Myeloma 6Leukemia, Myeloid, Acute 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Fallopian Tube Neoplasms 4Breast Neoplasms, Male 4Lymphoma, Follicular 3Kidney Neoplasms 3Hodgkin Disease 3Glioma 3Carcinoma, Renal Cell 3Osteosarcoma 2Neoplasms, Plasma Cell 2Neoplasms 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2

Interventions

Temozolomide 46Radiotherapy 36Bevacizumab 34Carmustine 13Erlotinib Hydrochloride 11Irinotecan 10sargramostim 7Thalidomide 7Chemotherapy, Adjuvant 7Carboplatin 7Radiation 6pembrolizumab 5Topotecan 5Magnetic Resonance Spectroscopy 5Filgrastim 5Drug Therapy 5Cyclophosphamide 5aldesleukin 4Tamoxifen 4Surgical Procedures, Operative 4Sorafenib 4O(6)-benzylguanine 4Gefitinib 4Etoposide 4Celecoxib 4cediranib 3Radiotherapy, Intensity-Modulated 3Radiotherapy, Conformal 3Peripheral Blood Stem Cell Transplantation 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gliosarcoma × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT01903330 2025-03-05

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Epitopoietic Research Corporation

Phase 2 Active not recruiting
84 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡